Company news
SeaStar Medical Holding Corporation news in 2024
SeaStar Medical Holding Corporation's news releases, calls and decks from 2024, newest first.
SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial
December 22, 2024
SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications
December 10, 2024
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
December 3, 2024
SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial
December 2, 2024
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
November 14, 2024
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 12, 2024
FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis
November 5, 2024
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
October 30, 2024
SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial
October 22, 2024
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers
October 21, 2024
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis
October 17, 2024
SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week
October 14, 2024
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
October 7, 2024
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
September 24, 2024
SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt
September 3, 2024
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
July 22, 2024
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner
July 11, 2024
SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 9, 2024
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device
July 2, 2024
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
June 9, 2024
SeaStar Medical Announces 25-for-1 Reverse Stock Split
June 5, 2024
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
May 13, 2024
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
April 29, 2024
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
April 16, 2024
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
March 26, 2024
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
March 11, 2024
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
January 31, 2024
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
January 25, 2024
SeaStar Medical Appoints David A. Green as Chief Financial Officer
January 10, 2024
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
January 8, 2024